INT116171

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.52
First Reported 2004
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 1.95
Pain Relevance 0.98

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (EDNRA, EDNRA) signal transduction (EDNRA, EDNRA) aging (EDNRA, EDNRA)
plasma membrane (EDNRA, EDNRA) signal transducer activity (EDNRA, EDNRA)
Anatomy Mention Frequency
superior 1
EDNRA (Homo sapiens)
EDNRA (Homo sapiens)
Pain Term Frequency Confidence Heat
antagonist 47 100.00 Very High Very High Very High
tetrodotoxin 1 76.48 Quite High
Inflammation 1 74.32 Quite High
fibrosis 2 73.64 Quite High
analgesia 2 70.08 Quite High
Pain 6 67.80 Quite High
agonist 1 64.72 Quite High
Pain refractory 1 62.08 Quite High
Bioavailability 2 60.32 Quite High
Opioid 1 59.44 Quite High
Disease Term Frequency Confidence Heat
Pulmonary Hypertension 98 98.68 Very High Very High Very High
Cancer 65 97.84 Very High Very High Very High
Increased Venous Pressure Under Development 6 93.96 High High
Ovarian Cancer 23 87.68 High High
Apoptosis 16 78.24 Quite High
Death 6 78.00 Quite High
Immunotherapy Of Cancer 2 74.40 Quite High
INFLAMMATION 1 74.32 Quite High
Fibrosis 1 73.64 Quite High
Pain 6 67.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Endothelin causes contraction of human esophageal muscularis mucosae through interaction with both ETA and ETB receptors.
Endothelin Binding (interaction) of ETA
1) Confidence 0.52 Published 2004 Journal Regul. Pept. Section Title Doc Link 14749038 Disease Relevance 0 Pain Relevance 0.20
Among various ETAR antagonists, ABT-627 (atrasentan, Abbott Laboratories, Abbott Park, IL) is an orally bioavailable endothelin antagonist that potently (Ki = 34 pM) and selectively binds to the ETAR, blocking signal transduction pathways implicated in cancer cell proliferation and other host-dependent processes promoting cancer growth (Figure 1).
ETAR Binding (binds) of ETAR associated with cancer and antagonist
2) Confidence 0.17 Published 2004 Journal J Transl Med Section Body Doc Link PMC436068 Disease Relevance 1.40 Pain Relevance 0.61
Selective agents with relative ETA:ETB affinity of greater than 100:1 have been developed, eg, sitaxentan, relative affinity 6500:1, which have also been shown to reduce endothelin-1 levels.19 Bosentan exhibits a relative ETA:ETB affinity of 20:1 by in vitro assays and is therefore classed as a dual ERA.20 Although ETA selectivity is attractive, these selective agents have not been shown to be superior to bosentan in clinical trials.
ETA Binding (affinity) of ETA in superior associated with antagonist
3) Confidence 0.06 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2725793 Disease Relevance 0.55 Pain Relevance 0.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox